ACAD
47.7
-0.49
-1.02%
AEMD
9.7
+0.2
+2.11%
APRI
1.4
+0.02
+1.45%
ARNA
4.05
-0.01
-0.25%
ATEC
1.36
0.00
0.00%
CNAT
4.41
-0.08
-1.78%
CRXM
0.29
-0.01
-3.33%
CYTX
0.421
-0.005
-1.290%
DXCM
84.93
+0.4
+0.47%
GNMK
8.12
+0.08
+1.00%
HALO
23.31
+0.28
+1.22%
ILMN
214.31
-2.39
-1.10%
INNV
0.158
+0.003
+1.935%
INO
7.15
-0.1
-1.38%
ISCO
0.043
0.00
0.00%
ISIS
55.3
+1.34
+2.48%
LGND
109.31
+0.57
+0.52%
LPTN
0.252
-0.013
-4.8430%
MBVX
1.9
-0.11
-5.47%
MEIP
1.49
0.00
0.00%
MNOV
3.63
-0.1
-2.68%
MRTX
27.82
-0.14
-0.50%
MSTX
0.424
-0.006
-1.441%
NBIX
49.56
+0.57
+1.16%
NUVA
55.58
+0.39
+0.71%
ONCS
5.79
-0.19
-3.18%
ONVO
3.19
-0.16
-4.78%
OREX
3.86
-0.1
-2.53%
OTIC
25.23
-0.74
-2.85%
QDEL
20.85
+0.23
+1.12%
RCPT
228
-0.56
-0.25%
RGLS
7.77
-0.22
-2.75%
RMD
55.9
+0.5
+0.90%
SCIE
0.016
-0.002
-10.5556%
SPHS
0.802
-0.042
-4.976%
SRNE
20.75
-0.42
-1.98%
TROV
7.5
-0.38
-4.82%
VICL
0.65
+0.022
+3.4873%
ZGNX
19.49
-0.11
-0.56%
ACAD
47.7
-0.49
-1.02%
AEMD
9.7
+0.2
+2.11%
APRI
1.4
+0.02
+1.45%
ARNA
4.05
-0.01
-0.25%
ATEC
1.36
0.00
0.00%
CNAT
4.41
-0.08
-1.78%
CRXM
0.29
-0.01
-3.33%
CYTX
0.421
-0.005
-1.290%
DXCM
84.93
+0.4
+0.47%
GNMK
8.12
+0.08
+1.00%
HALO
23.31
+0.28
+1.22%
ILMN
214.31
-2.39
-1.10%
INNV
0.158
+0.003
+1.935%
INO
7.15
-0.1
-1.38%
ISCO
0.043
0.00
0.00%
ISIS
55.3
+1.34
+2.48%
LGND
109.31
+0.57
+0.52%
LPTN
0.252
-0.013
-4.8430%
MBVX
1.9
-0.11
-5.47%
MEIP
1.49
0.00
0.00%
MNOV
3.63
-0.1
-2.68%
MRTX
27.82
-0.14
-0.50%
MSTX
0.424
-0.006
-1.441%
NBIX
49.56
+0.57
+1.16%
NUVA
55.58
+0.39
+0.71%
ONCS
5.79
-0.19
-3.18%
ONVO
3.19
-0.16
-4.78%
OREX
3.86
-0.1
-2.53%
OTIC
25.23
-0.74
-2.85%
QDEL
20.85
+0.23
+1.12%
RCPT
228
-0.56
-0.25%
RGLS
7.77
-0.22
-2.75%
RMD
55.9
+0.5
+0.90%
SCIE
0.016
-0.002
-10.5556%
SPHS
0.802
-0.042
-4.976%
SRNE
20.75
-0.42
-1.98%
TROV
7.5
-0.38
-4.82%
VICL
0.65
+0.022
+3.4873%
ZGNX
19.49
-0.11
-0.56%
Home » Archive by Category

Xconomy

The Near Death, and Second Life, of Cerulean Pharma

July 13, 2015 – 12:00 am

It’s not often that a biotech with a single drug in clinical testing can bounce back from a trial that not only fails, but bombs spectacularly. But by the skin of its teeth, Cerulean Pharma has…

[[Click headline to continue reading.]]

21st Century Cures Act Passes House, Now Must Navigate Senate

July 10, 2015 – 11:12 am

The U.S. House of Representatives took a big step this morning toward major changes in the federal government’s relationship to biomedical research, funding, and regulation. The chamber passed…

[[Click headline to continue reading.]]

“Global Health” Must Mean Global Health

July 9, 2015 – 3:20 am

The research community and pharmaceutical industry have made many life-saving and life-improving advances in global health over the past 20 years, and that’s certainly life-affirming news. But the…

[[Click headline to continue reading.]]

For Biotech Cowboys, It’s No Ride Into The Sunset

July 8, 2015 – 10:48 am

[Corrected 7/8/15, 3:48pm. See below.] Some people who’ve made it big in biotech drive fast cars. Some take outlandish vacations. Some don’t take any vacations at all. (I’m sure you…

[[Click headline to continue reading.]]

UCSD Asks Court to Restore Custody and Control of Alzheimer’s Data

July 7, 2015 – 6:24 pm

If there’s anything that’s clear in the recent donnybrook between UC San Diego and the University of Southern California, it’s that a 24-year study known as the Alzheimer’s Disease Cooperative Study…

[[Click headline to continue reading.]]

West Health COO Shelley Lyford to Succeed Nick Valeriani as CEO

July 7, 2015 – 5:00 am

West Health CEO Nick Valeriani plans to retire in September, after three years overseeing the San Diego-based nonprofit medical research organization founded by the Nebraska telemarketing billionaire…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Juno, UCSD v. USC, Natera, LSDF & More

July 6, 2015 – 3:33 pm

It was a short work week leading up to the 4th of July, but it was long on news out West. There were plenty of fireworks of the legal, political, and financial variety, with an academic lawsuit in…

[[Click headline to continue reading.]]

Biopharmaceutical Haiku, Round Two

July 6, 2015 – 12:00 am

Ebola doctors Heroic efforts admired Angels of mercy!   Genome sequencing Compare normal with patient Secrets revealed   Next-gen sequencing One big issue still out there Interpretation…

[[Click headline to continue reading.]]

Prenatal Tester Natera Now Shooting for $175M IPO

July 1, 2015 – 10:59 am

Natera of San Carlos, CA, has bumped the fundraising goal for its upcoming IPO to $175 million, according to a document filed today with the Securities and Exchange Commission. The maker of…

[[Click headline to continue reading.]]

AstraZeneca Working with Eolas Therapeutics on Anti-Addiction Drug

June 30, 2015 – 3:11 pm

Eolas Therapeutics, a Carlsbad, CA-based startup developing new drugs for treating addiction, said it has signed a global licensing and partnership agreement with AstraZeneca (NYSE: AZN) to advance…

[[Click headline to continue reading.]]